Mayo College of Medicine, Mayo Pediatric MS Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
Expert Opin Pharmacother. 2010 Mar;11(4):505-20. doi: 10.1517/14656560903527218.
Pediatric multiple sclerosis is an acquired inflammatory, demyelinating CNS disorder associated with recurrent episodes of neurologic dysfunction. Precise diagnosis is increasingly important as disease modifying therapies have been developed in adults and introduced into pediatric practice.
Literature published over the past two decades relating to pharmacologic treatment of multiple sclerosis (MS) in adults and children is reviewed, with emphasis on current publications.
This article reviews available research and clinical experience regarding treatment of acute episodes of CNS demyelination in children and adolescents, strategies for introduction and modification of disease-modifying therapies depending on disease course, and use of medication for symptomatic improvement in quality of life.
Pharmacotherapy for MS has been studied in adults but to a significantly lesser extent in children or adolescents. However, children and adolescents have different biology than adults in terms of drug metabolism, immune mechanisms and incomplete maturity of CNS myelin. Effectiveness as well as long-term safety needs to be studied in children and adolescents.
小儿多发性硬化症是一种后天获得的、炎症性的、脱髓鞘的中枢神经系统疾病，与反复发作的神经功能障碍有关。由于已在成人中开发出疾病修正疗法并引入儿科实践，因此精确诊断变得越来越重要。
过去二十年来与成人和儿童多发性硬化症（MS）药物治疗相关的文献综述，重点是当前的出版物。
本文综述了有关儿童和青少年中枢神经系统脱髓鞘急性发作的治疗、根据疾病过程引入和修改疾病修正疗法的策略，以及用于改善生活质量的对症药物治疗的现有研究和临床经验。
MS 的药物治疗在成人中进行了研究，但在儿童或青少年中研究的程度要低得多。然而，儿童和青少年在药物代谢、免疫机制和中枢神经系统髓鞘的不完全成熟方面与成人有不同的生物学特性。需要在儿童和青少年中研究其有效性和长期安全性。
